Volume 2  Issue 9

封面解读

刘鹏

胡亚伟

Diffuse midline glioma (DMG), H3K27-altered, is a lethal pediatric high-grade tumor, lacking effective treatment options, primarily depending on clinical trials. Epigenetic agent-based immunotherapy has shown promise, but the underlying mechanisms remain unclear. To address the scarcity of tumor samples, researchers utilize patient-derived tumor cells to explore DMG heterogeneity. The epigenetic characteristics of DMG include a loss of H3K27me3 and a gain of H3K27ac. To overcome the limitations of traditional techniques, we developed high-throughput in situ tagged immunoprecipitation sequencing (HiTIP-seq) utilizing InSMART, enabling 100 parallel assays from just 100 cells on a single chip. Using this new method, we analyzed epigenetic alterations in 3D cell cultures derived from DMG patients, discovering that combinations of epigenetic agents (such as panobinostat and tazemetostat) can reprogram histone modifications and drive transcriptome changes, notably upregulating WIF1. HiTIP-seq provides a new tool for DMG research, showcasing hope in the fight against this deadly disease, and may ultimately lead to effective treatment options in the future.

目     录

导     读

点击文章标题可跳转至原文^……

通讯作者：周俭

HIGHLIGHTS

• Due to different disease backgrounds, different surgical treatments for hepatocellular carcinoma (HCC) have been developed.

• Enhanced visualization methods and artificial intelligence provide benefits to both surgical oncologists and HCC patients.

• The emergence and evolution of new technologies have broken through the forbidden zone of HCC surgical treatment.

• With the exploration of innovative clinical trials, the surgical management pattern of HCC may be continuously revolutionized.

引用：

Ding ZB, Shi YH, Chen JF, et al. Recent advances in surgical management strategies for hepatocellular carcinoma. hLife 2024;2:439–453.

通讯作者：金腾川

文章讨论了人类跨膜蛋白盘状蛋白结构域受体1（DDR1）的结构、功能和病理特征，逐步揭示了DDR1在实体瘤微环境中的作用，并提出了其作为潜在的治疗靶点的可行性。

引用：

Bibi S, Zeng W, Zheng P, et al. Discoidin domain receptor 1 as a potent therapeutic target in solid tumors. hLife 2024;2:454–466.

引用：

Provance DW Jr, da Matta Durans A, Lechuga GC, et al. Surpassing the natural limits of serological diagnostic tests. hLife 2024;2:467–470.

通讯作者：刘鹏、章薇、胡亚伟

该研究基于微阵列芯片开发出一种高通量原位标记免疫沉淀测序技术（HiTIP-seq），不仅为弥漫性中线胶质瘤（Diffuse Midline Glioma, DMG）研究提供了新技术，更为其治疗新策略提供了科学依据。

引用：

Chen Z, Gao Q, Shang Y, et al. HiTIP-seq profiles epigenomic reprogramming of patient-derived diffuse midline glioma stem cells to epigenetic therapy. hLife 2024;2:471–487.

通讯作者：陈凌、李锋

引用：

Chen S, Zhang Z, Wang Q, et al. Nasal mucosal secretory immunoglobulin A but not serum antibodies is resistant to Omicron evasion. hLife 2024;2:488–491.

期刊简介

hLife由高福院士、董晨院士和Jules A. Hoffmann教授（2011诺奖获得者）领衔，是中国科学院微生物研究所主办，中国生物工程学会，浙江大学陈廷烨大健康学院，西湖大学医学院，上海市免疫治疗创新研究院和广州霍夫曼免疫研究所联合支持，与国际出版商爱思唯尔合作的健康科学领域综合性英文期刊。

hLife聚焦健康科学领域的前沿进展，旨在促进基础研究与临床应用的融合发展。期刊发表与医学相关各研究领域最新成果，学科领域包括（但不限于）病原生物学、流行病学、生理学、免疫学、结构生物学、疾病监测、肿瘤、药物、疫苗和健康政策等。

hLife是一本金色开放获取期刊，月刊出版；2022年成功入选“中国科技期刊卓越行动计划高起点新刊”；2023年11月正式创刊。目前已被DOAJ、Scopus数据库收录。

2025年前hLife接受的稿件免收文章处理费（APC）。

期刊网址：

https://www.sciencedirect.com/journal/hlife

邮箱｜ hlife@im.ac.cn

电话｜(86)10-64807577